Outsourcing

The $19.7 million contract will assist Emergent with the development of cGMP lots of three Ebola mAbs.

Baxter has initiated a voluntary recall of two lots of IV solutions due to the potential presence of particulate matter.

Evans Analytical Group expands into the pharmaceutical/biopharmaceutical industry with acquisition of ABC Laboratories.

The new project will increase fill/finish manufacturing capacity for select products on FDA’s Drug Shortage Index.

Catalent’s licensing of Excelimmune’s antibody combination therapy platform can enable more consistent, cost effective production of antibody combinations.

The addition of a new manufacturing line at Lonza’s Portsmouth, NH site enables Alexion to add dedicated product supply for 10 years.

The new facility expands the company’s commercial manufacturing capability at its Bend, Ore. site.

While all market signs are pointing up, memories of past setbacks may discourage CDMOs from expanding capacity.

Gil Roth, Founder and President of the Pharma & Biopharma Outsourcing Association speaks with BioPharm International.

Jim Miller, President of PharmSource, speaks with BioPharm International.

Jim Miller, President of PharmSource, spoke with BioPharm International about working with CMOs and CDMOs.

Jim Miller, President of PharmSource, discusses contract services trends.

The 12th Annual Report and Survey of Biomanufacturing is now available.

Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies

A new SGS Life Science Services laboratory outside Paris is designed for bio/pharmaceutical quality control testing.

Quality-risk management tools can assist biopharma companies in mitigating risks when outsourcing crucial elements of the drug-development process.

Automation and disposables continue to reduce human error.

Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.

Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.

Agency officials visit China to meet with Chinese regulators and industry representatives about keeping the pharma supply chain safe.

Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

The rapid testing of biologic raw materials can lead to greater efficiency.

Baxter voluntarily recalls select lots of IV solutions due to possible particulate matter.

Cornell Stamoran, Catalent Pharma Solutions vice-president, is elected to the board of trustees of the Pharma & Biopharma Outsourcing Association.